These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
233 related items for PubMed ID: 10660489
1. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. Pluijm G, Löwik C, Papapoulos S. Cancer Treat Rev; 2000 Feb; 26(1):11-27. PubMed ID: 10660489 [Abstract] [Full Text] [Related]
3. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P, Clézardin P. Cancer Res; 2007 Jun 15; 67(12):5821-30. PubMed ID: 17575150 [Abstract] [Full Text] [Related]
4. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Siclari VA, Guise TA, Chirgwin JM. Cancer Metastasis Rev; 2006 Dec 15; 25(4):621-33. PubMed ID: 17165131 [Abstract] [Full Text] [Related]
5. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. Chung LW, Baseman A, Assikis V, Zhau HE. J Urol; 2005 Jan 15; 173(1):10-20. PubMed ID: 15592017 [Abstract] [Full Text] [Related]
6. Mechanisms of tumor metastasis to the bone: challenges and opportunities. Reddi AH, Roodman D, Freeman C, Mohla S. J Bone Miner Res; 2003 Feb 15; 18(2):190-4. PubMed ID: 12568395 [Abstract] [Full Text] [Related]
7. Bisphosphonates for cancer patients: why, how, and when? Body JJ, Mancini I. Support Care Cancer; 2002 Jul 15; 10(5):399-407. PubMed ID: 12136223 [Abstract] [Full Text] [Related]
13. Microvascular density of breast cancer in bone metastasis: influence of therapy. Lörincz T, Tóth J, Szendröi M, Tímár J. Anticancer Res; 2005 Jul 15; 25(4):3075-81. PubMed ID: 16080568 [Abstract] [Full Text] [Related]
14. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Clines GA, Guise TA. Endocr Relat Cancer; 2005 Sep 15; 12(3):549-83. PubMed ID: 16172192 [Abstract] [Full Text] [Related]
15. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Guise TA, Chirgwin JM. Clin Orthop Relat Res; 2003 Oct 15; (415 Suppl):S32-8. PubMed ID: 14600590 [Abstract] [Full Text] [Related]
16. Clinical features of metastatic bone disease and risk of skeletal morbidity. Coleman RE. Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6243s-6249s. PubMed ID: 17062708 [Abstract] [Full Text] [Related]
17. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Mystakidou K, Katsouda E, Stathopoulou E, Vlahos L. Cancer Treat Rev; 2005 Jun 15; 31(4):303-11. PubMed ID: 16039956 [Abstract] [Full Text] [Related]
18. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL. Mol Cancer Res; 2005 Jan 15; 3(1):1-13. PubMed ID: 15671244 [Abstract] [Full Text] [Related]
19. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, Sanderson RD. Cancer Res; 2005 Jul 01; 65(13):5778-84. PubMed ID: 15994953 [Abstract] [Full Text] [Related]